Frisco-based InspectIR received the FDA emergency use authorization on Friday for its breathalyzer test, which tests for organic compounds associated with COVID-19 in a person’s breath. According to a study, the tests are more effective than the rapid antigen tests available for free from the U.S. government.
The first COVID-19 diagnostic test using a sample of a patient’s breath has been approved by the U.S. Food and Drug Administration. And the technology comes from a Frisco startup—impressive for a five-person team.
On Friday, InspectIR, a medical device company whose breathalyzer test was initially developed for far different uses, landed FDA emergency use authorization to begin public use of the test as the pandemic continues to ebb and flow across the country.
“As most of us have experienced, the world has changed due to the coronavirus pandemic,” said Tim Wing, InspectIR CEO, at the beginning of the pandemic. “We challenged our development teams with a simple question: ‘Can we help?’ We quickly realized our devices could identify COVID-19 in the breath and help with the unique circumstances facing the U.S. and the world right now.”
We are excited about the future of work…and know that InspectIR and our instrument can help alleviate some of your fears. If you are interested in learning more, please call 469.206.4555 or write email@example.com